Validation of Cellular Tests for Lyme borreliosis - VICTORY

Academisch Medisch Centrum0 个研究点目标入组 485 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•Healthy controls (1a): no specific inclusion criteria;Potentially cross-reactive controls (1b): one of several infectious or inflammatory diseases with criteria depending on the disease in question;Patients with disseminated Lyme borreliosis (1c): must have a confirmed diagnosis of disseminated LB (e.g., Lyme arthritis, neuroborreliosis, acrodermatitis chronica atroficans, Lyme-carditis), with clinical and laboratory criteria largely based on the case definitions of ESGBOR and published by Stanek and colleagues and must not have started treatment for the LB at the moment of inclusion or at most one week prior to the moment of inclusion. ;Cohort study (2): patients presenting at the specialized Lyme centers of the AMC or Radboudumc

•Healthy controls (1a): current Lyme borreliosis, having certain factors that may impair immunity (e.g., immunosuppressants or known immunodeficiency);Potentially cross-reactive controls (1b): ever an episode of Lyme borreliosis, recent tick bite, more than one potentially cross-reactive condition, having certain factors that may impair immunity (see above);Patients with disseminated Lyme borreliosis (1c): Signs or symptoms at inclusion attributed to a previous episode of LB.;Cohort study (2): no specific exclusion criteria

发起方